<DOC>
	<DOCNO>NCT02649608</DOCNO>
	<brief_summary>To evaluate safety , tolerability , pharmacokinetics , efficacy Lu AE04621 metabolite ascend oral dos Lu AE04621 patient Parkinson ` Disease .</brief_summary>
	<brief_title>An Exploratory Study Investigating Safety , Tolerability Pharmacokinetics Ascending Doses Lu AE04621 Parkinson Disease Patients</brief_title>
	<detailed_description>Dosing regimen decide dose conference prior cohort 2-8 . Dose level increase , maintain reduce cohort also within cohort . In cohort 3 patient Parkinson 's Disease treat 3 day , increase dose day . If deem appropriate dosing period may extend 4 day . In addition , 3 extra cohort 9 11 additional cohort might use , necessary address study objective . Up 33 patient enrol</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>The patient diagnose idiopathic Parkinson Disease ( consistent UK Parkinson ` Disease Society Brain Bank Criteria Diagnosis PD ) . The patient 's Hoehn Yahr Staging score ≤ 3 `` ON '' state . The patient experience motor fluctuation least 2.5 hour `` OFF '' period awake time predictable morning `` OFF '' episode , consistent within past 4 week . The patient currently good response LDOPA receive stable dose LDOPA ( ≥3 dos per day standard LDOPA ≥3 dose per day Carbidopa LDOPA , ExtendedRelease Capsules ) least four week prior screen . The patient cognitive impairment , define Mini Mental State Examination ( MMSE ) score ≤ 26 Screening Visit . The patient severe disable dyskinesia The patient take take disallowed recent concomitant medication ( CYP2D6 inhibitor , CYP 3A4 substrate , Dopamine agonists , 5 HT3 antagonist , Antiviral ( Amantadine ) ) Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>